Paysign: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Nov. 9, 2026, Paysign (NASDAQ:PAYS) announced a 43% year-over-year revenue increase to $30.8 million, driven by expansion in its pharmaceutical copay assistance business. The shift from transactional plasma donor card processing toward higher-margin patient affordability solutions is accelerating overall profitability and lifting gross margins. Three things management said stand out.

1. Patient Affordability Drives High-Margin Revenue Expansion

Pharma patient affordability revenue, which provides financial assistance cards for prescription medications, grew 110% year-over-year to $16.6 million as the number of active programs expanded. This higher-margin segment now generates more revenue than legacy payment processing for plasma collection centers.

In summary, patient affordability is the engine of our growth, and the pipeline remains robust and supports our outlook for the rest of the year and into 2027.
-- Mark Newcomer, President and Chief Executive Officer

2. Client Consolidation Creates Temporary Headwinds in Plasma

A plasma client is transitioning 113 collection centers to an existing banking partner by year-end, which will reduce fourth-quarter revenue by $1.5 million and gross profit by $700,000. Management expects to offset these losses over subsequent quarters through existing client expansion and new customer acquisition.

For the fourth quarter, we expect the transition to reduce revenue by $1.5 million and gross profit by $700,000.
-- Jeffery Baker, Chief Financial Officer

3. Dynamic Software Features Protect Client Capital and Lock In Customers

Paysign uses dynamic business rules, a software feature that prevents health insurance co-pay accumulators from absorbing pharmaceutical manufacturer assistance funds. By protecting client budgets, the software increases product stickiness and boosts average quarterly revenue per program.

In the third quarter alone, it insulated our clients from approximately $82.5 million in costs that co-pay maximizers and accumulator programs would otherwise have absorbed.
-- Mark Newcomer, President and Chief Executive Officer

Looking Ahead

Expanding margins and cash flow from legacy processing give Paysign flexibility to scale its software platform across new medical verticals. Management is watching program onboarding schedules and regulatory approval for its Apherion donor management software, which automates plasma collection operations.

Our full year outlook and confidence in the long-term earnings power of the platform are supported by continued strong patient affordability program momentum, higher year-over-year operating margins and a clean balance sheet as we move into the fourth quarter.
-- Jeffery Baker, Chief Financial Officer

With zero bank debt and $34.5 million in cash, the company is allocating capital to high-margin patient-assistance features while expanding its core processing operations.

The strength of our underlying business and our belief that we are well positioned to capitalize on the opportunities that lie ahead give us confidence that we will continue to deliver strong, meaningful year-over-year top and bottom line growth for the foreseeable future.
-- Mark Newcomer, President and Chief Executive Officer

The Motley Fool has positions in and recommends Paysign. The Motley Fool has a disclosure policy.